Home › Chronic Lymphocytic Leukemia › Ohio › Dayton
Chronic Lymphocytic Leukemia clinical trials in Dayton, OH
3 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Dayton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
- Dayton Physician Network, Dayton
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Dayton Physician LLC - Englewood, Dayton
- Greater Dayton Cancer Center, Kettering · 5 mi away
- Kettering Medical Center, Kettering · 5 mi away
- and 4 more
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Dayton Physician Network, Dayton
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH29 studies
- Durham, NC28 studies
- Washington, DC22 studies
- Seattle, WA22 studies
- Rochester, MN20 studies
- New York City, NY20 studies
- Houston, TX18 studies
- Baldwin Park, CA18 studies
- Cincinnati, OH15 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
Other studies in Dayton
- Lung Cancer14 studies
- Non-Small Cell Lung Cancer13 studies
- Steatotic Liver Disease8 studies
- Ovarian Cancer8 studies
- Heart Failure8 studies
- Endometrial Cancer8 studies
- Cancer (all types)7 studies
- Ulcerative Colitis7 studies
- Prostate Cancer7 studies
- Melanoma7 studies
- Breast Cancer6 studies
- Alzheimer's Disease6 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.